Peptides for Sleep Disorders — Evidence Review
Sleep disorders — insomnia, fragmented sleep, sleep apnea, circadian disruption — have well-validated first-line therapies. CBT-I (cognitive behavioral therapy for insomnia) has the strongest…
Sleep disorders — insomnia, fragmented sleep, sleep apnea, circadian disruption — have well-validated first-line therapies. CBT-I (cognitive behavioral therapy for insomnia) has the strongest evidence base of any insomnia treatment. CPAP for OSA is the standard. Pharmacology (melatonin, doxepin, suvorexant, eszopiclone) sits in second-line.
Peptide claims for sleep frequently outpace evidence. This guide reviews what's actually supported.
Peptides with the most relevant evidence
DSIP (Delta Sleep-Inducing Peptide)
Nonapeptide isolated from rabbit cerebral venous blood in the 1970s. Animal studies report sleep-promoting effects, particularly increased slow-wave (delta) sleep. Limited human data — early-1980s studies reported variable effects on sleep architecture in humans, and the peptide has not advanced to a recognized clinical sleep medication.
The mechanistic story is interesting; the human data is not strong enough to support routine use claims.
Selank
Anxiolytic peptide that modulates GABA and HPA-axis activity. For insomnia driven by anxiety or HPA-axis dysregulation, the mechanism is plausible. Russian research program data exists; Western RCT data is limited.
Use is more about reducing pre-sleep arousal than directly inducing sleep. For primary insomnia without anxiety driver, evidence is weaker.
Supporting cast — claims that outpace evidence
Epitalon
The Khavinson-program longevity-research peptide that's frequently associated with sleep claims in patient forums. Direct sleep-trial data is limited; mechanism for sleep-specific effects is not well-characterized. Claims tend to outpace evidence here as in other epitalon contexts.
What the evidence does not support
- BPC-157, TB-500, or tissue-repair peptides for sleep
- CJC-1295 + ipamorelin "for deeper sleep" — GH pulses occur during slow-wave sleep but elevating GH does not necessarily improve sleep architecture; this is reverse causality
- Use as substitute for proper sleep evaluation — insomnia and OSA have specific diagnostic and treatment pathways
- Use to compensate for inadequate sleep hygiene or untreated sleep apnea
Important practical considerations
Most sleep complaints respond best to:
- Sleep hygiene optimization
- CBT-I for insomnia (strongest evidence)
- CPAP for sleep apnea (mandatory if diagnosed)
- Treatment of underlying conditions (depression, anxiety, chronic pain)
- Conventional pharmacotherapy where appropriate
Peptide therapy is not first-line for any recognized sleep disorder.
Where to source
- DSIP vendor rankings — limited; lower independent testing volume
- Selank vendor rankings — limited
What we don't know
- Whether DSIP produces clinically meaningful improvement in human sleep architecture in modern trials
- Optimal dosing for selank in anxiety-driven insomnia
- Long-term safety of any peptide in chronic sleep-disorder use
- Whether peptide therapy meaningfully changes sleep stage distributions on polysomnography
Methodology
Read the full methodology.
This page is educational. Sleep disorders warrant proper evaluation — a sleep history, possible polysomnography, and assessment for primary causes. Peptide therapy is not standard care.